1 / 16

A3G – Automated Andersen Cascade Impactor It provide 25% reduction in time-to-market with $6 million cost reduction p

A3G – Automated Andersen Cascade Impactor It provide 25% reduction in time-to-market with $6 million cost reduction per drug !. A3G – A Great Investment. Product: A3G is an automated test system for Inhalation drugs-It will speed development of Inhalation Drugs by up to 25%-Propriety IP

min
Download Presentation

A3G – Automated Andersen Cascade Impactor It provide 25% reduction in time-to-market with $6 million cost reduction p

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A3G – Automated Andersen Cascade Impactor • It provide 25% reduction in time-to-market with $6 million cost reduction per drug !

  2. A3G – A Great Investment • Product: A3G is an automated test system for Inhalation drugs-It will speed development of Inhalation Drugs by up to 25%-Propriety IP • Market Opportunity: 132 Inhalation Drugs in clinical trials in the US present a $2.64Bn market opportunity • Investment needed: $3.5MM-Operating expenses for 2 yrs • Use of Funds: Product Development • Investor Returns: Exit at 3x annual sales in 5 years. 5th year sales conservatively projected at $ 32.5MM. Estimate IRR at 63%/year

  3. Product and Service • A3G is an automated Dose Determination (DD) system invented by LATech (global patent pending) • A3G will provide a throughput of 40 DDs per day compared to 2 DDs, typical of the current gold standard manual process • A3G technology can conduct the 10,000 DDs required to bring an inhalation drug to market 20x faster than current technology

  4. A3G Technology DEMO NOW BEFORE

  5. Market Opportunity • There are 132 inhalation drugs in clinical trials. Typically a drug takes 8 to 12 years to reach the market • Imagine a 25% reduction in time-to-market & the opportunity afforded by being 1st to market. • A3G is cost effective and produces better results faster than the existing technology

  6. Market Opportunity $27 Billion market for Inhalation Drugs as of 2010

  7. Market Opportunity • FDA prefers data from automated Dose Determination devices rather than manual processes • Dose determination for 132 inhalation drugs (1,320,000 DDs) in clinical trials provide a market opportunity of $1.12Bn to $2.64Bn • This provides for an opportunity to sell equipment to automate the DD process & sell DD services

  8. Competitive Landscape • Novi Systems • The Next Generation Impactor (MSP) • Laser diffraction (Sympatec, Malvern) • Astech • LATech has Global patent pending • The A3G automates the FDA Preferred Gold Standard—ACI, thus eliminating business risk for our customers

  9. Business Model & Target Audience • Equipment Business: • 16 Automated A3G machines. • 17% of the US market for 94 A3G s • - - - - - - - - - - - - - - - - - - - - - • VPs of Development – Large BioPharma The need to bring 132 inhalation drugs in clinical trials to market quickly, provides business opportunities • Service Business: • 30,000 DDs per year, starting with 10,000 DDs in year 2. • 5% of the US market for the 1,320,000 DDs • - - - - - - - - - - - - - - - - - - - - - • VPs Development – Small BioPharma • CROs

  10. Sales & Distribution Plans • In the community of BioPharma companies developing inhalable drugs—directsales • Service Collaborations are envisioned abroad, starting with Europe & India • Generate sales leads by: • Partnering with companies selling ACI • Collaborating with academia in generating joint publications in peer reviewed industry journals • Presenting papers & demonstrations in industry conferences & trade shows

  11. Management Team • Rajesh K. Maheshwari, CEO and founder • Developed award winning automation technologies over the past 26 years, including two Automated Andersen Systems • MBA (Rutgers), MSEE (RPI) , B.Sc.(Eng) • Krishna Maheshwari, Director of Business Development • Held positions with increasing levels of responsibility at Microsoft, Amazon, Symantec and Millipore • Closed 100 deals worth $60MM • MBA (Harvard),ME & BS (Cornell)

  12. Advisory Board • Dr. PravinSoni – President, PharmaCRO, LLC. Previously VP R&D with Alexza, Cygnus • Dr. Rodney Woods - Director, MannKind Corp The LATech Team • Seven associates in the US and 36 in India. • 140 man-years experience in designing & developing automation systems for the BioPharma industry

  13. Operational Capability • 7 Associates in the US. • EpiComm Technologies in Pune, India. ISO 9000 qualified Software Development Facility – staff of 36 engineers.

  14. Use of Proceeds -- $3.5 MM Investment NOTES: R&D & Manufacturing costs include the production of one each of Semi-Automated & Automated versions of A3G Operating expenses for 2 Years

  15. Five -Year Financial Projection 32.7 20.3 18.0 11.0 9.4 6.7 4.0 1.1 -1.7

  16. A3G – A Great Investment • Propriety Product • Urgent Market Need • Motivated Management Team with High Profile Board of Advisors • Great Return on Investment -- IRR of 63%/year

More Related